ImmuCell Corporation — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-1.6% -$125K
$8M
Cost of Revenue↓-4.1% -$204K
$5M
Gross Profit↑+2.8% +$79K
$3M
R&D↓-7.4% -$61K
$759K
D&A↑+6.0% +$40K
$709K
Operating Income↑+103.5% +$595K
$20K
EBITDA↑+6.0% +$40K
$709K
Interest Expense↓-22.1% -$30K
$106K
Interest Income↓-12.6% -$5K
$32K
Other Income/Expense
$-62K
Pretax Income↑+80.7% +$565K
$-135K
Tax Provision↓-45.2% -$3K
$3K
Net Income↑+80.1% +$562K
$-140K
Gross Margin↑+1.6pts
38.2%
Operating Margin↑+9.9pts
0.4%
Net Margin↑+9.1pts
-2.5%
Effective Tax Rate↓-3.1pts
-3.3%
Deferred Tax Assets
$0
Deferred Tax Liabilities
—
DTA Valuation Allowance↑+9.0% +$333K
$4M
NOL Carryforwards
—
ETR (Continuing Operations)↓-0.6pts
-1.1%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↑+6.0pts
7.8%
ETR Foreign Differential (pp)↑+0.0pts
0.0%
Operating Lease Cost↓-20.5% -$22K
$85K
Revenue YoY Variation↓-53.7pts
-1.6%
Income YoY Variation↑+52.0pts
103.5%
Revenue QoQ Variation↑+9.6pts
38.5%
Income QoQ Variation↓-155.0pts
-96.5%